Developed by BioArctic and Eisai, the injectable version of lecanemab-irmb aims to streamline the treatment journey for patients with mild cognitive impairment or mild dementia. Starting in late August 2026, the approved regimen requires two 250 mg injections administered weekly. This method mirrors the clinical efficacy of intravenous infusions while reducing the logistical strain on patients, caregivers, and healthcare facilities.
FDA Approves At-Home Subcutaneous Injection for Early Alzheimer’s
The U.S. Food and Drug Administration has cleared Leqembi Iqlik for the initiation of Alzheimer's treatment, marking a shift toward at-home care. The subcutaneous autoinjector allows patients to begin therapy outside clinical settings, providing a weekly alternative to traditional intravenous infusions for those in early stages of the disease.
Clinical data from the Phase 3 Clarity AD long-term extension study confirms that the subcutaneous delivery achieves exposure levels comparable to IV administration. Safety profiles remain consistent between the two methods, with ARIA-E rates showing no significant increase in the subcutaneous cohort. Beyond clinical outcomes, the transition to an autoinjector addresses the practical demands of long-term care. An acceptability study involving 100 participants reported that 94% of patients and care partners found the device intuitive, signaling a potential decrease in the burden of frequent clinic visits and nursing requirements.
Comments (0)
No comments yet. Be the first!